Low risk — use of or exposure to this product is not likely to cause adverse health consequences.
Nicotine polacrilex lozenge Recalled by GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline Due to Failed Lozenge Specifications; Lozenges are overly thick, overly...
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline directly.
Affected Products
Nicotine polacrilex lozenge, 4 mg, Cherry Flavor, 72 count cartons, 81 count cartons, and 108 count cartons. OTC. Labeled a. Nicorette, Distributed By: GlaxoSmithKline Consumer Healthcare, L.P., Moon Township, PA 15108. Made in Switzerland. 72 Count NDC: 0135-0513-01, 81 Count NDC: 0135-0513-02, 108 Count NDC: 0135-0513-03 b. Nicotine Lozenge Kroger, Distributed by: The Kroger Company, Cincinnati, Ohio 45202, 72 Count NDC:30142-664-01, and c. Nicotine Walgreens, Distributed by: Walgreen Co., 200 Wilmot Rd., Deerfield, IL 60015. 72 Count NDC: 0363-9200-01.
Quantity: 304,332 72 Ct Vials, 85,080 81 Ct Vials 22,992 108 Ct Vials
Why Was This Recalled?
Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.
Where Was This Sold?
This product was distributed nationwide across all 50 states.
About GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline
GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline has 10 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report